Source: EURLEX
Language: en
Format: md

Judgment of the General Court (Third Chamber) of 23 November 2022 –  
Zeta Farmaceutici v EUIPO – Specchiasol (EUPHYTOS)

(Case T‑515/21) (
[1](#t-ECR_62021TJ0515_INF_EN_01-E0001)
)

(EU trade mark – Invalidity proceedings – EU word mark EUPHYTOS – Earlier EU figurative mark EuPhidra – Proof of genuine use of the earlier mark – Article 56(2) and Article 43(2) of Regulation (EC) No 40/94 (now Article 64(2) and Article 47(2) of Regulation (EU) 2017/1001) – Relevant periods – Submission of evidence for the first time before the Board of Appeal – Discretion of the Board of Appeal – Classification of new or complementary evidence – Article 95(2) of Regulation 2017/1001 – Article 27(4) of Delegated Regulation (EU) 2018/625)

| 1. | EU trade mark – Decisions of EUIPO – Legality – Examination by the EU judicature – Criteria – EUIPO examination guidelines – Effect  (European Parliament and Council Regulation 2017/1001)  (see paragraph 43) |

| 2. | EU trade mark – Surrender, revocation and invalidity – Examination of the application – Proof of use of the earlier mark – Genuine use – Meaning – Criteria for assessment  (Council Regulation No 40/94, Art. 43(2) and (3))  (see paragraphs 52, 57) |

| 3. | EU trade mark – Procedural provisions – Invalidity proceedings – Facts and evidence not submitted in support of the claim for invalidity within the time limit – Account taken – Discretion of the Board of Appeal  (European Parliament and Council Regulation 2017/1001, Art. 95(2); Council Regulation No 40/94, Art. 56(2); Commission Regulation 2018/625, Art. 27(4))  (see paragraphs 79, 80, 91-93, 95-97) |

| 4. | EU trade mark – Appeals procedure – Action before the EU judicature – Power of the General Court to alter the contested decision – Limits  (European Parliament and Council Regulation 2017/1001, Art. 72(3))  (see paragraph 116) |

Operative part

The Court:

| 1. | Annuls the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 10 June 2021 (Case R 2094/2019-1); |

| 2. | Dismisses the action as to the remainder; |

| 3. | Orders EUIPO to bear its own costs and to pay those incurred by Zeta Farmaceutici SpA. |

---

(
[1](#c-ECR_62021TJ0515_INF_EN_01-E0001)
) [OJ C 422, 18.10.2021](./../../../legal-content/EN/AUTO/?uri=OJ:C:2021:422:TOC).

[Top](#document1)